Remove Drug Development Remove FDA Approval Remove Laboratories
article thumbnail

De-risking drug discovery with predictive AI

Broad Institute

Srijit Seal, a visiting scholar at the Carpenter-Singh Lab in the Broad's Imaging Platform , trained multiple predictive machine learning models to identify chemical and structural drug features likely to cause toxic effects in humans. A fourth is in the works.

article thumbnail

Automated red blood cell exchange: bridging treatment gaps in sickle cell disease care

Drug Target Review

Currently, three FDA-approved disease-modifying drug therapies are available: hydroxyurea, crizanlizumab and L-glutamine, though each has limitations that affect patient compliance. The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease. JAMA Netw Open. 2023.44546.

Disease 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Power of AI in Drug Discovery and Development

The Connected Lab

For patients suffering from an illness with no approved treatment, the wait can be unnerving. To this day, more than 400 million people suffer from rare diseases and 95% of rare diseases lack an FDA approved treatment 3. How is AI being applied in Drug Discovery efforts?

article thumbnail

Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference

The Pharma Data

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

article thumbnail

Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021

The Pharma Data

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

article thumbnail

Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting

The Pharma Data

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

article thumbnail

Regeneron Announces Investor Conference Presentations

The Pharma Data

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.